TCL Archive Reinventing NCI: Natural Products Screen Closes; NCI Targets Drug Resistance December 13, 1996
TCL Archive Taxol Plus Carboplatin Increased Survival Of NSCLC In Patients 70 And Older June 25, 2010
TCL Archive New benchmark for CCSG award funding will be lowered from 20 percent of NCI research base to 15 percent, the program’s “reality ratio,” Karen Antman tells NCAB. October 8, 2004
TCL Archive Xeloda, Taxotere, Herceptin Combination May Benefit Invasive Breast Cancer January 25, 2008
